Related Experiment Video
Updated: Jul 5, 2025
Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis
Youn Kyung Kee1,2, Hayne Cho Park2,3, Su Jin Yoon4
1Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, Republic of Korea.
Insights
Regdanvimab significantly reduced mortality in hospitalized COVID-19 patients on hemodialysis. This finding offers a promising therapeutic option for this vulnerable end-stage renal disease population.
Area of Science:
- Nephrology
- Infectious Diseases
- Pharmacology
Background:
- Limited effective treatments exist for COVID-19 in end-stage renal disease (ESRD) patients.
- COVID-19 poses a high mortality risk for ESRD patients undergoing hemodialysis (HD).
Purpose of the Study:
- To evaluate the effectiveness of regdanvimab in reducing mortality among COVID-19 patients on hemodialysis.
- To identify factors associated with mortality in this patient group.
Main Methods:
- An observational retrospective study involving 230 COVID-19 patients on HD.
- Comparison of in-hospital mortality between patients who received regdanvimab and those who did not.
Main Results:
- Regdanvimab administration was associated with a significantly lower in-hospital mortality rate (13.0% vs. 32.0%, p = 0.001).
- Multivariate analysis identified malignancy, low oxygen saturation (SPO2 <95%), and antibiotic use as mortality risk factors, while regdanvimab administration was protective.
Conclusions:
- Regdanvimab administration demonstrates a beneficial effect on the prognosis of hospitalized COVID-19 patients on hemodialysis.
- Regdanvimab should be considered a potential therapeutic option for COVID-19 patients with end-stage renal disease on hemodialysis.
Background:
Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (COVID-19), there are lack of effective and proven treatments for end-stage renal disease (ESRD). The present study aims to evaluate the effectiveness of regdanvimab on mortality in COVID-19-infected patients on hemodialysis (HD).
Methods:
We conducted an observational retrospective study in 230 COVID-19-infected patients on HD, of whom 77 (33.5%) were administered regdanvimab alone or in combination with dexamethasone or remdesivir during hospitalization (regdanvimab group) and 153 patients (66.5%) were not (no regdanvimab group). The primary outcome was in-hospital mortality. We compared mortality rates according to the use of regdanvimab and investigated the factors associated with mortality.
Results:
Fifty-nine deaths occurred during hospitalization, 49 in the no regdanvimab group (32.0%) and 10 in the regdanvimab group (13.0%), and the mortality rate was significantly higher in the no regdanvimab group than that in the regdanvimab group (p = 0.001). Multivariate Cox regression analysis showed that malignancy (p = 0.001), SPO2 of <95% at admission (p = 0.003), and administration of antibiotics and regdanvimab (p = 0.007 and p = 0.002, respectively) were significantly associated factors with mortality.
Conclusion:
Regdanvimab administration is beneficial in improving prognosis in hospitalized COVID-19 patients on HD. Considering the vulnerability to infection and high mortality of ESRD patients, regdanvimab may be considered as a therapeutic option in COVID-19 patients on HD.
Related Concept Videos
01:27Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:22Heart Failure Drugs: Diuretics
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...